| Literature DB >> 28932883 |
Susana Barreda-García1, Rebeca Miranda-Castro1, Noemí de-Los-Santos-Álvarez1, Arturo J Miranda-Ordieres1, María Jesús Lobo-Castañón2.
Abstract
Highly sensitive testing of nucleic acids is essential to improve the detection of pathogens, which pose a major threat for public health worldwide. Currently available molecular assays, mainly based on PCR, have a limited utility in point-of-need control or resource-limited settings. Consequently, there is a strong interest in developing cost-effective, robust, and portable platforms for early detection of these harmful microorganisms. Since its description in 2004, isothermal helicase-dependent amplification (HDA) has been successfully applied in the development of novel molecular-based technologies for rapid, sensitive, and selective detection of viruses and bacteria. In this review, we highlight relevant analytical systems using this simple nucleic acid amplification methodology that takes place at a constant temperature and that is readily compatible with microfluidic technologies. Different strategies for monitoring HDA amplification products are described. In addition, we present technological advances for integrating sample preparation, HDA amplification, and detection. Future perspectives and challenges toward point-of-need use not only for clinical diagnosis but also in food safety testing and environmental monitoring are also discussed. Graphical Abstract Expanding the analytical toolbox for the detection of DNA sequences specific of pathogens with isothermal helicase dependent amplification (HDA).Entities:
Keywords: Helicase; Isothermal; Molecular test; Nucleic acid amplification; Pathogen detection
Mesh:
Substances:
Year: 2017 PMID: 28932883 PMCID: PMC7079856 DOI: 10.1007/s00216-017-0620-3
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.142
Fig. 1Scheme of the helicase-dependent amplification system, adapted from reference [7]. (1) Unwinding dsDNA by helicase and stabilization of ssDNA by SSB; (2) annealing of primers, and (3) elongation of primers by DNA polymerase
Fig. 2Right panel: schematic representation of HDA assays with homogeneous fluorescent monitoring, by using dual-labeled probes (a), TaqMan (b) hairpin ones. Left panel: a previous sequence-specific sample preparation employing RNA probes along with magnetic particles modified with an antibody specific for RNA-DNA hybrids boosts assay performance in clinical samples
Fig. 3Schematic of lateral flow HDA assay (left), symmetric (right), asymmetric DNA amplification
Fig. 4Hybridization-based on-surface capture of HDA amplicons: (1) homogeneous asymmetric HDA, (2) specific capture of biotinylated ss-amplicon, and (3) enzyme labeling and optical detection of the enzymatic product
Summary of published helicase-dependent amplification methods for pathogen detection
| Pathogen | Detection | LD (copies/reaction) | HDA time (min) | HDA T (°C) | Sample | turnaround time (min) | Ref |
|---|---|---|---|---|---|---|---|
|
| Gel electrophoresis | – | 60 | 65 | cultures | 90a | [ |
|
| Gel electrophoresis | 4 pg RNA | 60 | 65 | Leaf tissue | – | [ |
|
| Gel electrophoresis | 1 ng | 90 | 65 | Insect infected mixed cereals | – | [ |
|
| PAGE | 0.0125 pg | 45 | 65 | Stool | – | [ |
|
| Real-time | 1 | 90 | 65 | Cervical swabs | 90 | [ |
|
| Real-time | 10 | 90 | 65 | Cervical swabs | 90 | [ |
|
| Real-time | – | 30 | 62 | Plasmid DNA | 30 | [ |
|
| Real-time | 300 | 90 | 65 | Plasmid DNA | 90 | [ |
|
| Real-time | 100 cfu/mL | 60 | 65 | Cultures | 60 | [ |
|
| Real-time (comercial) | – | 45 | – | Vaginal swab/ urine | 45 | [ |
|
| Echem real-time | 105 | 80 | 65 | Plasmid DNA | 80 | [ |
|
| TaqMan real-time | 50 | 60 | 65 | Genomic DNA | 60 | [ |
|
| TaqMan real-time | 50 (pXO1 gene) | 90 | 63 | Genomic DNA | 90 | [ |
|
| TaqMan real-time | 50 (pXO2 gene) | 90 | 63 | Genomic DNA | 90 | [ |
|
| TaqMan real-time | 50 (multiplex) | 90 | 63 | Genomic DNA | 90 | [ |
|
| Fluorescence | 100 | 10 | 65 | Artificial sputum | – | [ |
|
| Fluorescence | 5 cfu/mL | 90 | 65 | Spiked milk powder | 120 | [ |
| 50 cfu/mL | 90 | 65 | Spiked pork meat | 120 | [ | ||
|
| Fluorescence | 5–10 cells | 60-120 | 65 | Spiked collection media | – | [ |
| 25 cells (multiplex) | 90-120 | 65 | Spiked collection media | – | [ | ||
|
| Fluorescence | 5–10 cells | 60-120 | 65 | Spiked collection media | – | [ |
| 25 cells (multiplex) | 90-120 | 65 | Spiked collection media | – | [ | ||
|
| LFD | 50 | 20 | 65 | Urine | 35 | [ |
|
| LFD | 20 | 60 | 65 | Stool | 75 | [ |
|
| LFD | 50 cfu/mL | 60 | 65 | Bacteria blood culture | 80 | [ |
|
| LFD | – | 35 | 64 | pharyngeal swab | 45 | [ |
|
| LFD | 5.5 | 60 | 64 | Genital lesion swab | 75 | [ |
|
| LFD | 34.1 | 60 | 64 | Genital lesion swab | 75 | [ |
|
| LFD | 470 copies/mL | 75 | 64 | Dried blood spots | 95 | [ |
|
| LFD | 50 copies | 90 | 64 | genomic DNA | 105 | [ |
|
| LFD | 200 parasites/μL | 120 | 64 | Blood samples | 135 | [ |
|
| LFD | 1000 cells | 30 | 65 | Synthetic urine | 50 | [ |
|
| LFD | 50 | 90 | 65 | Horse nasal swabs | 105 | [ |
|
| LFD | 2 | 30 | 65 | Cultures | 50 | [ |
|
| LFD | 35–40 cfu | 60 | 64 | Bacterial culture | 90 | [ |
| 1.3–1.9 cfu/mL | 60 | 64 | spiked chicken, infant cereal, milk | 90b | [ | ||
|
| LFD | 100 cfu/mL | 60 | 65 | waswater / eggs | 77a | [ |
| 1000 cfu/mL | 60 | 65 | milk /juice | ||||
|
| Hyb Enzym optic | 10 | 60 | 60 | Gastric biopsies | 240 | [ |
|
| Hyb Enzym optic | 1 (mecA gene) | 45 | 65 | Blood samples | 75 | [ |
|
| Hyb Enzym optic | 1–250 cfu (tuf gene) | 45 | 65 | Blood samples | 75 | [ |
|
| Hyb Enzym optic | 1 | 40 | 65 | Clinical samples | – | [ |
|
| Hyb Enzym optic | 10 | 30 | 65 | genomic DNA | 35 | [ |
|
| Hyb Enzym optic | – | 40 | 65 | Blood cultures | 60a | [ |
|
| Hyb Enzym optic | – | 90 | 65 | --- | [ | |
|
| Hyb Enzym optic | 10 pg/μL | 75 | 65 | Artificially infected leaf tissue | 135 | [ |
|
| Hyb Enzym optic | 1 cfu (manual) | 45 | 65 | Fecal samples | 60a | [ |
| 10 cfu (automated) | 45 | 65 | Fecal samples | 90a | [ | ||
|
| Hyb Enzym chronoA | 15 | 90 | 65 | Clinical samples | – | [ |
|
| Hibridization DPV | 0.1 ng/μL | 90 | 65 | Synthetic DNA | 360 | [ |
|
| Hibridization FRET | 37 zmol | 60 | 65 | Synthetic DNA | – | [ |
|
| On-surface fluorescence | 50,000 cells | 120 | 65 | Genomic DNA | – | [ |
|
| On-surface fluorescence | 5×105 cells (multiplex) | 120 | 65 | Genomic DNA | – | [ |
|
| On-surface fluorescence | 1.32×105 cells | 120 | 65 | Genomic DNA | – | [ |
|
| On-surface fluorescence | 1.32×106 cells (multiplex) | 120 | 65 | Genomic DNA | – | [ |
|
| On-surface enzym chronoA | 10 | 90 | 65 | Genomic DNA | – | [ |
|
| On-surface enzym optic | 100 | 90 | 65 | Genomic DNA | – | [ |
C.T.: Clamidia trachomatis, N.G.: Neisseria gonorrhoeae, M.T.: Mycobacterium tuberculosis, HSV: herpes simplex virus, HPV: human papiloma virus, HIV: human immunodeficiency virus, Echem: electrochemical, Hyb: hybridization, Enzym: enzymatic, ChronoA: chronoamperometry, DPV: differential pulse voltammetry
aIncluding extraction.
b+2–4 h of enrichment.